AFP awarded at NPPA’s 2023 "Best Of Photojournalism Competition"
The NPPA (National Press Photographers Association) Awards have honoured AFP photographer Luis Tato with three prizes in the Science, Science Story and Politics Story categories.
London (AFP) | 18/01/2026 - 12:30:19 | Irish FM says threatened US tariffs 'completely unacceptable'
Seoul (AFP) | 18/01/2026 - 12:07:48 | Italian PM calls threatened US tariffs over Greenland a 'mistake'
Paris (AFP) | 18/01/2026 - 10:38:18 | Trump also 'has a lot to lose' from threatened tariffs: French minister
Beirut (AFP) | 18/01/2026 - 08:56:40 | Kurdish-led forces withdraw from Syria's largest oil field: monitor
Damascus (AFP) | 18/01/2026 - 06:34:12 | Syria state media says two main bridges on Euphrates destroyed in Raqa
Nuuk (AFP) | 18/01/2026 - 00:23:30 | Greenland minister praises European countries for response to Trump tariffs threat
Damascus (AFP) | 17/01/2026 - 22:45:04 | Syrian army says has taken airport in key Kurdish-held city
Kampala (AFP) | 17/01/2026 - 21:57:56 | Internet restored in Uganda after election blackout: AFP
Brussels (AFP) | 17/01/2026 - 20:44:44 | EU warns against Trump's tariffs threat over Greenland
Paris (AFP) | 17/01/2026 - 20:44:10 | Iran schools to reopen Sunday after one-week closure: media
Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/Experian's 2026 Data Breach Industry Forecast Now ...
The NPPA (National Press Photographers Association) Awards have honoured AFP photographer Luis Tato with three prizes in the Science, Science Story and Politics Story categories.
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose p...